Here’s what you need to know:
1. Stem cell technologies and point of care blood products both remain experimental and require more research.
2. Orthopedic surgeon Adam Anz, MD, of the Andrews Institute said, “We are making sure that there is evidence around safety and effectiveness before we make claims or advertise about regenerative medicine because at this point it needs more studying since it’s experimental.”
3. Bone marrow aspirate concentrate and platelet rich plasma don’t require FDA approval for the way Andrews Institute uses them.
4. Andrews Institute is currently conducting research on regenerative medicine’s impact on ligament, cartilage and osteoarthritis treatment.
5. Dr. Anz noted that Andrews Institute founder and famed orthopedic sports medicine physician James Andrews, MD, believes the arthroscope was the first great advancement in sports medicine while the second is bound to be regenerative medicine.
More articles on sports medicine:
2 OrthoCarolina physicians treat 3 Carolina Panthers players’ injuries — 5 things to know
NewYork-Presbyterian Queens partners with St. John’s University athletics
Concussion-leading sport isn’t what you’d expect: 5 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
